MCM6/CDC6 is a potential biomarker for renal clear cell carcinoma
YANG Tuo,CAI Ke-ke,ZHAO Peng
Department of Urology, Tianjin NanKai Hospital, NanKai University Affiliated NanKai Hospital, Tianjin Key Laboratory of Acute Abdominal Disease Organ Injury and Chinese and Western Medicine Repair, Tianjin 300381, China
Abstract:
Objective To explore the correlation between the expression of MCM6, CDC6 and malignant biological behavior in renal clear cell carcinoma tissues. Methods 77cases of renal clear cell carcinoma tissue confirmed by pathology were used as the study group, and homologous distal normal renal tissue was used as the control group for the MCM6. CDC6 study; Based on the GEPIA database, the expression of MCM6 and CDC6 in renal clear cell carcinoma tissue and normal tissue was compared using monoclonal antibody immunohistochemistry technology; qRT-PCR and Western blot were used to detect the effect of shRNA on MCM6 expression: CCK8 and colony formation assay were used to detect the in vitro proliferation results of HTB-47 and CRL-1932 cell lines. Results Compared with normal renal tissue, MCM6, CDC6 was significantly upregulated in renal clear cell carcinoma tissue, and upregulation of MCM6 was associated with reduced disease-free survival rate (P<0.05); Knocking down the MCM6 gene of HTB-47 and CRL-1932 cell lines can significantly inhibit the proliferation of tumor cells and significantly block the tumor cell division cycle staying in the G2/M phase; The expression of MCM6 was significantly correlated with the volume size of renal cell carcinoma (P=0.010), and according to the GEPIA database, there was a significant correlation between CDC6 and MCM6 (P<0.01). All expression results were further validated by immunohistochemical staining. Conclusion The upregulation of MCM6 expression is related to the malignant behavior and clinical progression of renal clear cell carcinoma, which can regulate cell proliferation by affecting the cell cycle. In renal clear cell carcinoma tissues, the expression levels of MCM6 and CDC6 are significantly upregulated and closely related, indicating that MCM6/CDC6 may become a potential biomarker for predicting renal clear cell carcinoma and a new therapeutic target for targeted therapy of this disease.
